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Background
sJIA refractory to immunosuppressants including meth-
otrexate and TNF-a inhibitors can lead to severe dis-
abilities. Excessive IL-6 production has been implicated
in the pathoetiology of sJIA.
Aim
To determine the efficacy and safety of TCZ, an IL-6
receptor inhibitor, in patients (pts) with sJIA treated for
52 weeks (wks) in the ongoing, 3-part, 5-year, phase 3
TENDER study.
Methods
Pts (N=112) 2–17 years with active sJIA for ≥6m o n t h s
were randomized 2:1 to TCZ (8 mg/kg if body weight
≥30 kg; 12 mg/kg if <30 kg) or placebo every 2 wks for
12 wks in part 1; all pts received open-label (OL) TCZ
in part 2. Pts who escaped to OL TCZ in part 1 also
entered part 2. Oral corticosteroid (CS) tapering was
permitted at wks 6 and 8 in part 1 and in the OL exten-
sion in the presence of ACR70 response, ESR <20 mm/
h, and absence of fever. Efficacy data included pts who
reached wk 52 of TCZ treatment (n=88); safety data
considered all pts (N=112).
Results
Proportions of TCZ pts who achieved JIA ACR30 +
absence of fever or JIA ACR70/90 increased to wk 52
(Table). Number of joints with active arthritis or with
limitation of movement decreased from 19.8±15.7 and
19.8±15.6, respectively, to 3.0±7.0 and 7.5±11.7 at wk 52
(45% of pts had 0 active joints). CHAQ-DI score
improved from 1.7±0.9 to 0.7±0.8 at wk 52. Physician
global assessment VAS and pt/parent global assessment
VAS improved from 64.9±22.3 and 58.7±24.4, respec-
tively, to 9.7±12.8 and 12.6±18.5 at wk 52. CS dose
decreased from 0.30±0.20 mg/kg/d to 0.06±0.08 at wk 52;
48% discontinued CSs. 33 serious AEs (SAEs) occurred in
25 pts; 12 SAEs were considered related (remotely, possi-
bly, or probably) to TCZ (rate: 0.23/pt year [PY] in part
1, 0.25/PY in part 2). 15 serious infections occurred; 6
(gastroenteritis, varicella, septic arthritis, otitis media,
pharyngotonsillitis, upper respiratory tract infection)
were considered related to TCZ; all resolved and none
led to discontinuation. 12 pts withdrew (4, AEs; 4, insuffi-
cient response). One pt died of a suspected tension pneu-
mothorax considered unrelated to treatment.
Conclusions
TENDER 1-year results demonstrate that TCZ is highly
effective and generally well tolerated in pts with sJIA.
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JIA ACR30 + absence of fever,
n (%)
9 (24) 64 (85) 77 (88)
JIA ACR70, n (%) 3 (8) 53 (71) 78 (89)
JIA ACR90, n (%) 2 (5) 28 (37) 57 (65)
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